Center for Lymphoid Malignancies opens in New York

ColumbiaDoctors Eastside and Columbia University Medical Center are announcing the creation of a specialized medical center dedicated to blood cancers, the Center for Lymphoid Malignancies.

The Center for Lymphoid Malignancies will feature over 25 physicians, nurses, clinical trial coordinators, regulatory specialists, laboratory scientists, and staff. Their sole focus will be on lymphoid cancers (a term that includes lymphoma and leukemia), and many of these renowned professionals have been working together for many years.

Owen A. O'Connor, MD., Ph.D. will serve as the Director. The Center for Lymphoid Malignancies will offer:

-- A group of physicians highly-skilled and experienced in managing patients with all forms of lymphoid cancers, including all subtypes of non-Hodgkin's lymphoma, Hodgkin's Disease, chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia/lymphoma (ALL),

-- While focused on patients with lymphoid malignancies, the physicians also bring an expertise in most blood related cancers, including multiple myeloma, myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML).

-- A portfolio of nearly 20 Phase 1, 2 and 3 clinical trials offering some of the newest treatments available for these diseases. This portfolio of clinical studies devoted to lymphoid malignancies is among the largest in the country.

-- Highly skilled nursing care, including nurses with experience from the most prominent cancer centers in the country, capable of helping patients navigate the complexities of an unusual disease, and its treatment.

-- Skilled psychiatric and psychosocial support for patients.

Source: MarketWatch

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap